AzTrials
AzTrials

Continuous Renal Replacement Therapy (CRRT)iCRRTNCT07365111

Insights Into the Continuous Renal Replacement Therapy to Critical Ill Patients

An observational study of Continuous Renal Replacement Therapy (CRRT) and Acute Kidney Injury, run by University of Alberta at 1 site in Canada.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This is a multinational, prospective, observational study designed to characterize patient demographics, prescription parameters, and process measures of continuous renal replacement therapy (CRRT) in intensive care units (ICUs) worldwide. Read more about this study

Who is it for?
Any age
What is being tested?
continuous renal replacement therapy
Type of treatment
Medical device
How many people
100,000 participants
Where
1 siteCanada
Study dates
31 Mar 2027to 31 Dec 2036
How long will I take part?
90 Days
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Patients with new acute kidney injury and initiation of continuous renal replacement therapy who are admitted to an intensive care unit and who have received continuous renal replacement therapy for at least 24 hours will be eligible for this study.

Who may be able to join

  • Admission to an intensive care unit
  • CRRT therapy

Who cannot join

  • End-stage kidney disease
  • CRRT <24 hours

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Oleksa Rewa, MD MSc FRCPC contact

178026332850

rewa@ualberta.ca

Fadi Hammal, MD MSc contact

15879907454

hammal@ualberta.ca

Canada1 site
  • University of Alberta

    Edmonton, Alberta, T6G 2G3

    Fadi Hammal, 5879907454, hammal@ualberta.ca

Other trials in Canada

About this study

Official title: Insights Into the Characteristics, Prescription and Delivery of Continuous Renal Replacement Therapy to Critical Ill Patients - The iCRRT Data Registry

This is a multinational, prospective, observational study designed to characterize patient demographics, prescription parameters, and process measures of continuous renal replacement therapy (CRRT) in intensive care units (ICUs) worldwide. The study aims to examine similarities and differences in CRRT practices and outcomes among critically ill adult patients across a global network of medical centers.

The goal is to develop a large, comprehensive repository of data on CRRT practices and outcomes. This repository will enable characterization of variation in standard CRRT practices across medical centers. Natural variability in practice patterns-both between and within centers-will provide an opportunity to compare outcomes associated with different approaches and to generate high-quality preliminary data to inform future interventional trials.

Read more

Primary Objective

  • To describe global patient characteristics, CRRT modalities, and clinical outcomes among patients receiving CRRT.

Secondary Objectives

  • To compare clinical outcomes across geographic regions and CRRT modalities.
  • To identify patient-level and practice-level predictors of outcomes.
  • To assess the impact of comorbid conditions (e.g., diabetes mellitus) on CRRT outcomes.

Exploratory Objectives

  • To evaluate long-term renal outcomes and patient-reported quality of life.
  • To explore health economics and resource utilization related to CRRT.

Study Population All patients receiving CRRT as part of routine clinical care in the ICU at participating centers will be eligible for inclusion.

Data Collection The study will support an epidemiological assessment of patients undergoing CRRT, including, but not limited to, demographics, underlying disease states, severity of illness, physiological support, indications for CRRT, and clinical outcomes. Outcomes of interest include ICU and hospital mortality, ICU and hospital length of stay, and renal recovery.

Read the detailed description

1.0 Rationale The goal of this study is to develop a large repository of data on CRRT practices and outcomes, enabling characterization of similarities and differences in standard CRRT practices across medical centers. Natural variability in practices will provide an opportunity to compare outcomes associated with different practice patterns and generate important preliminary data to inform future interventional trials.

2.0 Background Despite the accumulation of high-quality evidence, the prescription, delivery, and maintenance of continuous renal replacement therapy (CRRT) remain highly variable across clinical settings. This persistent heterogeneity reflects uncertainty in key aspects of CRRT practice and underscores the need for a comprehensive, international evaluation. The international CRRT (iCRRT) initiative was established to systematically characterize global CRRT practices, identify regional variation, and inform strategies to optimize the delivery of this life-sustaining therapy for critically ill patients.

Acute kidney injury (AKI) is among the most common and severe complications encountered in critical illness, affecting more than half of patients admitted to intensive care units (ICUs). Approximately 6% of ICU patients require renal replacement therapy (RRT), a subgroup in whom hospital mortality remains exceedingly high, frequently approaching or exceeding 50%. Although AKI is associated with substantial morbidity, mortality, and healthcare utilization, no interventions have been shown to consistently reverse established kidney injury. Management, therefore, remains largely supportive, with RRT reserved for patients with advanced or refractory disease.

For critically ill patients, particularly those with hemodynamic instability, CRRT has become the predominant RRT modality in many high-income countries. Since the original description of continuous arteriovenous hemofiltration more than three decades ago, technological and procedural advances have transformed CRRT into a widely adopted and routinely applied therapy. Compared with intermittent hemodialysis (IHD), CRRT offers superior hemodynamic tolerance, continuous solute control, and more precise fluid management. These perceived advantages form the basis of the 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines, which recommend CRRT over intermittent modalities in hemodynamically unstable patients . Nevertheless, despite its central role in contemporary critical care, substantial variation in CRRT practice persists across institutions and individual providers.

At the same time, there is increasing recognition that traditional clinical outcomes alone may incompletely capture the impact of critical illness and its treatments. Evidence increasingly supports the routine use of patient-reported outcome measures (PROMs) to improve patient-clinician communication, enhance patient satisfaction, and positively influence health-related quality of life (HRQL). In this context, the Alberta-based EMPATHY study is evaluating the effectiveness and cost-effectiveness of systematic PROMs collection in chronic RRT programs, examining associations with patient experience, clinical outcomes, HRQL, and healthcare utilization.

Despite existing guideline recommendations-most notably regarding target effluent dose and the preferential use of regional citrate anticoagulation - guidance remains limited for many fundamental components of CRRT delivery, including modality selection, anticoagulation protocols, electrolyte supplementation, and fluid balance strategies. This lack of consensus reflects the limited strength of the current evidence base, which is largely derived from small, single-center studies. Moreover, despite the high-risk nature of patients receiving CRRT, quality indicators and patient safety outcomes related to CRRT delivery have been insufficiently studied.

In this context, the investigators describe the protocol for a prospective observational study designed to evaluate CRRT practices among critically ill adult patients across an international consortium of medical centers. The primary objective is to establish a large, multicenter repository capturing patient characteristics, CRRT prescription and delivery patterns, and associated clinical outcomes. By leveraging natural variation in practice across healthcare systems, this study aims to generate robust comparative data and provide a foundation for the design of future interventional trials aimed at improving CRRT care and outcomes worldwide.

3.0 Research Question What are the similarities and differences in CRRT practices and outcomes among critically ill adult patients across a network of global medical centres?

4.0 Objectives Primary Objective

-To describe global patient characteristics, CRRT modalities, and clinical outcomes among patients receiving CRRT.

Secondary Objectives

  • To compare outcomes across geographic regions and CRRT modalities.
  • To identify patient-level and practice-level predictors of outcomes.
  • To assess the impact of comorbidities (e.g., diabetes mellitus, chronic obstructive pulmonary disease, cerebrovascular accidents and hypertension) on CRRT outcomes.

Exploratory Objectives

  • To evaluate long-term renal outcomes and quality of life.
  • To explore health economics and resource utilization related to CRRT.

5.0 Methods Design and Setting This is a multinational, prospective, observational study designed to characterize patient demographics, prescription parameters, and process measures of continuous renal replacement therapy (CRRT) in intensive care units (ICUs) worldwide.

Study Population The study will be conducted in ICUs at participating centers globally. All critically ill patients receiving CRRT as part of routine ICU care will be eligible for inclusion. Inclusion criteria are intentionally broad to capture a systems-level population suitable for evaluating practice patterns and outcomes.

Inclusion Criteria

  • Admission to the ICU
  • Receipt of CRRT therapy Exclusion Criteria
  • End-stage kindey disease
  • CRRT < 24 hours

Sample Size No formal sample size calculation will be performed. All eligible patients will be included.

Interventions CRRT administered as part of routine ICU care. This is an observational study; no study-related clinical interventions will be performed, and no biospecimens will be collected.

Data Collection A comprehensive range of data will be collected, including patient characteristics at enrolment, CRRT modalities and treatment courses, fluid balance, medications, and clinical outcomes. Electronic medical records will serve as the primary data source.

Each site will assign a de-identified patient identification number through the registry database; no direct patient identifiers will be uploaded. Sites without electronic medical records may manually enter de-identified data into a secure, password-protected, web-based interface. All electronic data transmission will use encryption technology to ensure data privacy and security.

The registry will comply with applicable privacy regulations, including the Health Insurance Portability and Accountability Act (HIPAA; 45 CFR Parts 160 and 164), including provisions related to de-identified data and limited data sets.

All sites will use standardized electronic case report forms. Measurement units will be customized to reflect local laboratory reporting practices, with automatic conversion and storage of values in standardized units for centralized analysis.

Statistical Analysis Data will be summarized using standard descriptive statistical methods. Associations between patient characteristics, CRRT initiation and prescription parameters, and clinical outcomes (including mortality, length of stay, and duration of AKI) will be evaluated using analysis of variance (ANOVA) for normally distributed variables or the Kruskal-Wallis test for non-normally distributed variables. Multivariable models will be developed, including variables with a univariate significance level of p < 0.20 and/or based on clinical relevance as determined by investigators judgment. Additional analyses will be conducted to address specific research questions as they arise.

Primary Outcomes An epidemiological assessment of patients undergoing CRRT, including, but not limited to, demographics, disease states, severity of illness, physiological support, indications for CRRT, and clinical outcomes. Outcomes include ICU and hospital mortality, ICU and hospital length of stay, and renal recovery.

Being tested
continuous renal replacement therapy
Keywords
Continue Renal Replacement Therapy, Dialysis, Acute Kidney Injury, Intensive Care Unit
Medical subject headings
Acute Kidney Injury, Critical Illness

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • continuous renal replacement therapyDevice

    Also called CRRT

    We will include any critically ill patient admitted to an intensive care unit requiring dialysis

Study groups in NCT07365111
Study groupRoleWhat they receive
PatientsAny patients admitted to the ICU and required CRRT
Receives: Device: continuous renal replacement therapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mortality

    Patient survival at the time of ICU discharge

    Measured: Up to 28 days

Secondary outcomes (5)
  1. Hospital mortality

    Patient survival status during their hospitalization

    Measured: Up to 90 days

  2. ICU length of stay

    Duration of ICU stay

    Measured: Up to 90 days

  3. Hospital length of Stay

    Duration of hospital stay

    Measured: Up to 90 days

  4. Renal recovery

    1. Return of serum creatinine (SCr) to within 50% of baseline; 2) no longer receiving dialysis

    Measured: Up to 90 days

  5. Adverse events

    Any adverse events adjudicated to CRRT-related events

    Measured: Up to 90 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Jan 2026
  2. Study start31 Mar 2027 (estimated)
  3. Primary completion31 Mar 2036 (estimated)
  4. Study completion31 Dec 2036 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
100,000 participants (estimated)
Target duration
90 Days
IDs, dates and publications
ClinicalTrials.gov ID
NCT07365111
Sponsor's protocol ID
Pro00160785
Acronym
iCRRT
Status last verified
Sep 2026
First submitted
17 Dec 2025
Last updated
9 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Continuous Renal Replacement Therapy (CRRT) and Acute Kidney Injury, run by University of Alberta at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 9 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Oleksa Rewa, MD MSc FRCPC (178026332850, rewa@ualberta.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mortality (time frame: Up to 28 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in